研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Southwest Hospital, China[3]Women Hospital, School of Medicine, Zhejiang University[4]Anhui Provincial Cancer Hospital[5]Sichuan Cancer Hospital and Research Institute[6]Qilu Hospital of Shandong University[7]Beijing Friendship Hospital[8]Tianjin Medical University General Hospital[9]West China Second University Hospital[10]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[11]Xiangya Hospital of Central South University[12]Gansu Provincial Maternal and Child Health Care Hospital[13]Zhejiang Cancer Hospital[14]Shengjing Hospital
研究目的：
It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors >4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.
